Antibodies associated with HIV control

Peak revenue. This peak is an explicitly hypothetical illustrative figure for cohort-envelope consistency only — it is NOT a forecast. The asset is a discovery-stage correlate; JHU's realizable value is licensing the epitope/immunogen IP to a vaccine developer or a public-health consortium (Gates/NIH/HVTN/IAVI), or non-exclusive research use — not product revenue. HIV-prevention vaccines are overwhelmingly procured at public-health/tiered pricing in the highest-burden settings, so even a hypothetical successful prophylactic immunogen would not behave like a blockbuster Western mAb; $500M is a conservative placeholder anchored to a public-health-priced prophylactic addressing community viral-load reduction, deliberately set well below commercial-mAb figures and not implying a fundable standalone product.

WACC. A 20% rate reflects discovery-stage risk in the single hardest vaccine indication in modern medicine: no lead immunogen, the sole efficacy basis is an n=13 observational correlate, and the two completed Env-targeted HIV-vaccine efficacy trials (Imbokodo, Mosaico) both failed — risk far above a standard 12–14% biotech rate.

This asset is not a therapeutic antibody. It is a discovery-stage immuno-epidemiologic finding: using the VirScan massively-multiplexed antibody-profiling platform on samples from the HPTN 071 (PopART) HIV-prevention trial, Grant-McAuley et al. (Frontiers in Immunology, 2023) found that pre-infection antibody reactivity to an epitope in the HR2 domain of gp41 was associated with HIV-controller status and lower post-infection viral load (with a C2-gp120 epitope associated with the opposite). JHU's own listing is explicit that the technology is 'in the discovery stage' and that the proposed forward path is 'immunization against this epitope' in uninfected people — i.e. a prophylactic vaccine concept, not a passive monoclonal-antibody drug. The pinned 'monoclonal_antibody' modality bucket is therefore a label-vs-reality mismatch: the natural antibody is a correlate, and the disclosed development path is active immunization. The entire efficacy basis is an association observed in just 13 controllers — hypothesis-generating, not a validated protective immunogen, and with no lead candidate, no defined immunogen, and no IND.

Because this is a basic-science discovery rather than a therapeutic asset, the rNPV is not the decision criterion here, which is why the asset is classified as grant_non_commercial; the engine envelope is shown only for cohort consistency. The honest comparators are mechanism-true archetypes and cautionary precedents, not product anchors. HVTN 133 (NCT03934541) is the closest: a Phase 1 vaccine that immunized seronegative adults against a gp41 epitope, induced binding antibodies broadly but only low-titer neutralization in 2 of 5, and did not advance. Imbokodo (HVTN 705) and Mosaico (HVTN 706) are the field reality — fully resourced Env-targeted HIV vaccines that failed at Phase 2b/3, in a field with no approved vaccine after roughly 40 years. Anchored to that archetype and failure rate, the engine result is -$19.2M to -$11.2M, with a base rNPV of -$15.2M and cumulative PoS of 0.3%; that spread is illustrative only — JHU's realizable value is licensing the epitope/immunogen IP into a public-health vaccine effort (NIH/Gates/HVTN/IAVI), not equity-funded product development.

Verdict: scientifically interesting correlate, not a fundable standalone product. It earns rank 32 on the rubric's clinical-relevance signal (HIV functional-cure / community-viral-load unmet need), a high antibody/modality_pos score, and high IRA exposure plus a neutral 'other'-indication whitespace — not on being an investable asset. Hence grant_non_commercial: the value path is IP licensing into the publicly funded HIV-prevention pipeline, where a CMO would judge it as an early target-discovery lead, not a product.